QS-21

Ready-to-use syringe replaces two-vial format, simplifying administration for clinicians; approval based on technical comparability and keeps same indication and dosing.

Approval now explicitly includes immunocompromised adults; Phase IIIb showed non‑inferior immune response versus older adults and a safety profile consistent with prior trials.